Terrie Curran - Jun 12, 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran
Stock symbol
ARQT
Transactions as of
Jun 12, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 08:17 PM
Previous filing
Mar 3, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Curran Terrie Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran 2025-06-16 0001690298

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +7.61K +75.05% $0.00 17.7K Jun 12, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Award $0 +20.6K $0.00 20.6K Jun 12, 2025 Common Stock 20.6K $13.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 16, 2024, maintained by the Company.
F2 The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney